Which Patients at Risk of Cardiovascular Disease Might Benefit the Most from Inclisiran? Polish Experts' Opinion. The Compromise Between EBM and Possibilities in Healthcare

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2022 May 20

PMID 35591826

Authors

Maciej Banach

Jaroslaw Kazmierczak

Przemyslaw Mitkowski

Krystian Wita

Marlena Broncel

Mariusz Gasior

Marek Gierlotka

Robert Gil

Piotr Jankowski

Maciej Niewada

Adam Witkowski

Affiliations

Soon will be listed here.

Citing Articles

Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS): study design and methodology.

Banach M, Fronczek M, Osadnik T, Gach A, Strapagiel D, Slomka M Arch Med Sci. 2024; 20(5):1452-1460.

PMID: 39649254 PMC: 11623186. DOI: 10.5114/aoms/192147.

Dyslipidaemia management in pregnant patients: a 2024 update.

Lewek J, Bielecka-Dabrowa A, Toth P, Banach M Eur Heart J Open. 2024; 4(3):oeae032.

PMID: 38784103 PMC: 11114474. DOI: 10.1093/ehjopen/oeae032.

RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges.

Yuan W, Shi X, Lee L Mol Ther Nucleic Acids. 2024; 35(2):102195.

PMID: 38741614 PMC: 11089380. DOI: 10.1016/j.omtn.2024.102195.

Summary of 2023 and the biggest challenges for the "Archives of Medical Science" on its 20 Anniversary.

Banach M Arch Med Sci. 2024; 20(1):1-7.

PMID: 38414450 PMC: 10895965. DOI: 10.5114/aoms/183608.

New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets.

Wojtasinska A, Kucmierz J, Tokarek J, Dybiec J, Rodzen A, Mlynarska E Int J Mol Sci. 2023; 24(23).

PMID: 38069058 PMC: 10706703. DOI: 10.3390/ijms242316735.

References

Ray K, Reeskamp L, Laufs U, Banach M, Mach F, Tokgozoglu L . Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2021; 43(8):830-833. DOI: 10.1093/eurheartj/ehab718. View

Pajak A, Szafraniec K, Polak M, Drygas W, Piotrowski W, Zdrojewski T . Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland. Arch Med Sci. 2016; 12(4):687-96. PMC: 4947614. DOI: 10.5114/aoms.2016.59700. View

Jankowski P, Koziel P, Setny M, Paniczko M, Haberka M, Banach M . Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey. J Clin Med. 2021; 10(16). PMC: 8396933. DOI: 10.3390/jcm10163711. View

Dyrbus K, Gasior M, Penson P, Ray K, Banach M . Inclisiran-New hope in the management of lipid disorders?. J Clin Lipidol. 2019; 14(1):16-27. DOI: 10.1016/j.jacl.2019.11.001. View

Henney N, Banach M, Penson P . RNA Silencing in the Management of Dyslipidemias. Curr Atheroscler Rep. 2021; 23(11):69. PMC: 8410691. DOI: 10.1007/s11883-021-00968-7. View

Vrablik M, Seifert B, Parkhomenko A, Banach M, Jozwiak J, Kiss R . Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis. 2021; 334:66-75. DOI: 10.1016/j.atherosclerosis.2021.08.035. View

Jankowski P, Topor-Madry R, Gasior M, Ceglowska U, Eysymontt Z, Gierlotka M . Innovative Managed Care May Be Related to Improved Prognosis for Acute Myocardial Infarction Survivors. Circ Cardiovasc Qual Outcomes. 2021; 14(8):e007800. DOI: 10.1161/CIRCOUTCOMES.120.007800. View

Cordero A, Santos-Gallego C, Facila L, Rodriguez-Manero M, Bertomeu-Gonzalez V, Castellano J . Estimation of the major cardiovascular events prevention with Inclisiran. Atherosclerosis. 2020; 313:76-80. DOI: 10.1016/j.atherosclerosis.2020.09.021. View

Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E . Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32):2459-2472. PMC: 5837225. DOI: 10.1093/eurheartj/ehx144. View

10.

Banach M, Penson P . What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?. Cardiovasc Res. 2019; 115(3):e26-e31. DOI: 10.1093/cvr/cvy301. View

11.

Lewek J, Konopka A, Starostecka E, Penson P, Maciejewski M, Banach M . Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland. J Clin Med. 2021; 10(19). PMC: 8509252. DOI: 10.3390/jcm10194302. View

12.

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

13.

Dyrbus K, Gasior M, Desperak P, Nowak J, Osadnik T, Banach M . Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes - Data from the TERCET registry with 19,287 patients. Pharmacol Res. 2018; 139:460-466. DOI: 10.1016/j.phrs.2018.12.002. View

14.

Banach M, Penson P, Vrablik M, Bunc M, Dyrbus K, Fedacko J . Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021; 166:105499. DOI: 10.1016/j.phrs.2021.105499. View

15.

Dyrbus K, Gasior M, Desperak P, Trzeciak P, Nowak J, Penson P . Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry. Atherosclerosis. 2021; 333:16-23. DOI: 10.1016/j.atherosclerosis.2021.08.024. View

16.

Whitehead K, Langer R, Anderson D . Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009; 8(2):129-38. PMC: 7097568. DOI: 10.1038/nrd2742. View

17.

Solnica B, Sygitowicz G, Sitkiewicz D, Cybulska B, Jozwiak J, Odrowaz-Sypniewska G . 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci. 2020; 16(2):237-252. PMC: 7069434. DOI: 10.5114/aoms.2020.93253. View

18.

Hawranek M, Grygier M, Bujak K, Bartus S, Gierlotka M, Wojakowski W . Characteristics of patients from the Polish Registry of Acute Coronary Syndromes during the COVID-19 pandemic: the first report. Kardiol Pol. 2021; 79(2):192-195. DOI: 10.33963/KP.15756. View

19.

Raal F, Kallend D, Ray K, Turner T, Koenig W, Wright R . Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020; 382(16):1520-1530. DOI: 10.1056/NEJMoa1913805. View

20.

Khan S, Naz A, Masood M, Shah R . Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020; 134:69-73. DOI: 10.1016/j.amjcard.2020.08.018. View